Zogenix - Top 20 VC deals of 2007

Company: Zogenix
Based: San Diego, CA
Amount: $78.8M
Investors: Abingworth Management, Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, Undisclosed Investor

Scoop: Zogenix is developing CNS disorders and pain treatments. In December 2007 the company submitted an NDA for sumatriptan DosePro, a needle-free, disposable, subcutaneous delivery system for migraine. Zogenix is also working on a Phase III controlled release opioid product it in-licensed from Elan.

More News:
Zogenix gains $60M in new VC funds. Report
Zogenix raises $18M in preferred stock financing. Report

Zogenix - Top 20 VC deals of 2007
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.